Why Failure is Falling Upwards ​​​​​​​– Learn from Entac Medical Founder, Buddy Lyons, and Find Out How RESI became Part of the Success Story

19 Nov

By Rory McCann, Marketing Manager & Conference Producer, LSN

Failure is an unwelcome companion on the entrepreneurial journey, and one most founders avoid at all costs. To Buddy Lyons, Founder and CEO of Entac Medical, failure (or the threat of it) can play an integral role in a company’s development, growth, and eventual success. Entac Medical is developing non-invasive devices for diagnosis, particularly to surgical patients. Hear their story and listen to my conversation with Buddy about the earliest days of Entac, and what got them through the most trying times.

 

CMO Dr. John Cromwell is representing Entac Medical at Life Science Nation’s Healthtech Partnering Week, January 11-15, 2021. He is leading a panel discussion on AI-enabled technology within medical devices at 4D Meets AI, January 14-15, 2021. Learn more and sign up to join at https://4dmeetsai.com/.

1,500+ Meetings at Digital RESI November

19 Nov

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Life Science Nation (LSN)’s latest Redefining Early Stage Investments (RESI) conference is wrapping up today after three days chock-full of partnering. With over 500 attendees representing 30 countries and spanning 5 continents, our conferences provide early-stage startups with a venue to connect with investors and strategic partners from all around the globe.

This week’s RESI saw 10,000 meeting requests sent and more than 1,500 meetings taking place. Additionally, companies and investors are connecting offline, using the RESI partnering platform to create new relationships or maintain existing ones. In addition to partnering, the live-streamed panels and pitch sessions received large audiences, with over 200 live attendees total, with more still to come for today’s sessions.

Couldn’t make it to Digital RESI November? Want to attend another? Make sure to register for Digital RESI January, taking place January 11-13, 2021. Take advantage of RESI’s unique partnering capabilities and vetted investor attendees and save up to $150 on the super early bird rate until December 4. We hope to see you in the New Year!

Boost Your Exposure at Healthtech Partnering Week – Apply for the Innovator’s Pitch Challenge (IPC)

19 Nov

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireWe are now accepting applications for the Innovator’s Pitch Challenge at Healthtech Partnering Week, taking place January 11-15, 2021.

The Innovator’s Pitch Challenge (IPC) is an opportunity for start-ups to boost their exposure and showcase their technology to conference attendees, particularly investors. Each company will be provided with a dedicated landing page on our virtual agenda, which will include their pitch video, slide deck, executive summary, and any other materials companies wish to feature on their page. In addition, the companies pitch to a panel of judges featuring active investors and prominent industry experts, and participate in a live Q&A. These sessions will provide valuable insights and feedback, as well as build connections between fundraising founders and potential strategic partners.

If you are a fundraising CEO, you do not want to miss out on this opportunity.

Example of a Company’s Landing Page

Hot Investor Mandate: Global Investment Group Seeks Opportunities in Early-Stage, Software-Based Digital Health Technologies

19 Nov

A global investment group invests through multiple vehicles and has over $1B targeted on healthcare and life science under management. The firm recently launched a new vehicle to invest in digital health technologies. The group will invest $0.5-1M, mainly in seed-series A companies developing software-based digital technologies.

The firm is interested in software-based digital health companies. The group will not invest in wearables or smart devices. The firm invests primarily in B2B or B2B2C companies, and looks for technologies that have clear cost saving or revenue generating aspect for clients. While the firm will invest globally, they are looking for companies targeting the US market.

The firm is a very active investor, leveraging their network and broad-cross sector activity to help their portfolio companies. The group is looking for companies that, at minimum, have a viable understanding of the US healthcare market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Venture Capital Firm Invests Up to $25M in Therapeutics, With Strong Interests in Platform Technologies Based in North America

19 Nov

A firm with offices in the USA invests in seed and Series A rounds, and has a strong preference for being the first institutional investor in a company. The firm typically reserves a total of $25 million to invest over the life of a portfolio company. The firm invests in the USA and Canada, and typically makes about 5 allocations per year.

The firm is primarily focused on therapeutics, and generally will no longer invest in technologies with a medical device regulatory pathway. The firm prefers to invest in platform technologies that have attained significant preclinical proof of concept data, preferably with published data and evidence that shows reproduction of theory. The firm prefers that platform technologies have potential to bring therapeutics to market in the short-term. The firm will consider therapeutic opportunities in any indication space and is agnostic to modality (i.e. small molecule, large molecule, cell/gene therapy). Additionally, the firm invests in biotech research tools, such as sequencing technologies and discovery platforms.

The firm prefers to work with strong scientific teams. The firm invests only in the USA and Canada, and does not consider international opportunities unless the company has a significant US presence. The firm generally does not invest in companies that have previously received investments from an institutional investment firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Chinese Multi-Billion Dollar Fund Can Invest Up to $50M In All Life Science & Healthcare Opportunities with China Market Potential

19 Nov

A venture firm based in China has a multi-billion dollar fund and is interested in companies raising seed/angel to Series A rounds and provides investments that can range up to $50M depending on the opportunity. Series B round will also be considered occasionally in terms of the potentiality. The firm seeks opportunities globally, though it has a preference for companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Seed Fund Focuses on Applied AI Technologies Within Digital Health, Diagnostics, and R&D Services

19 Nov

A seed fund based in the USA focuses on applied AI technologies, and invests in three verticals: Digital Health, Enterprise and Automation. Within Digital Health, the firm invests in companies developing AI/ML, software-based technologies in the sectors of digital health, diagnostics and R&D services. The firm will invest $250K-500K in seed-stage companies based in the US and Canada, and will consider all companies, as long as they have a good business model.

Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will consider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery.

The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: